Serum and salivary anti-capsular antibodies in infants and children vaccinated with octavalent pneumococcal conjugate vaccines, PncD and PncT
- PMID: 11567764
- DOI: 10.1016/s0264-410x(01)00250-x
Serum and salivary anti-capsular antibodies in infants and children vaccinated with octavalent pneumococcal conjugate vaccines, PncD and PncT
Abstract
We studied the immunogenicity of two octavalent pneumococcal (Pnc) conjugate vaccines; Pnc polysaccharides (PS) of serotypes 3, 4, 6B, 9V, 14, 18C, 19F, and 23F were conjugated to diphtheria or tetanus toxoid (PncD and PncT, respectively). Fifty healthy Finnish infants were vaccinated at the ages of 2, 4, 6, and 15 months with either PncD or PncT. Serum IgG antibodies to the vaccine serotypes were analysed by enzyme-linked immunosorbent assay (EIA). All eight PSs induced a significant antibody response both after the primary series and after the booster. Response to PncD was higher for PSs 3, 9V, 14 and 18C and to PncT for serotype 4. Salivary IgA and IgG anti-Pnc antibodies were measured for serotypes 4, 6B, 9V, 14, 18C, and 19F. Mucosal antibodies were found rarely after the primary series but in a greater proportion after the booster. In conclusion, both vaccines were immunogenic.
Similar articles
-
Serum and salivary anti-capsular antibodies in infants and children immunized with the heptavalent pneumococcal conjugate vaccine.Pediatr Infect Dis J. 2001 Jan;20(1):25-33. doi: 10.1097/00006454-200101000-00006. Pediatr Infect Dis J. 2001. PMID: 11176563
-
Pneumococcal conjugate vaccination in toddlers: mucosal antibody response measured as circulating antibody-secreting cells and as salivary antibodies.Pediatr Infect Dis J. 1999 Sep;18(9):764-72. doi: 10.1097/00006454-199909000-00005. Pediatr Infect Dis J. 1999. PMID: 10493335 Clinical Trial.
-
Safety and immunogenicity of two octavalent pneumococcal conjugate vaccines in American Indian infants.Vaccine. 2004 Mar 12;22(9-10):1260-4. doi: 10.1016/j.vaccine.2003.09.026. Vaccine. 2004. PMID: 15003655 Clinical Trial.
-
Immunogenicity of pneumococcal conjugate vaccines.Pediatr Infect Dis J. 2000 Apr;19(4):388-93. doi: 10.1097/00006454-200004000-00035. Pediatr Infect Dis J. 2000. PMID: 10783041 Review.
-
Protective immunity of pneumococcal glycoconjugates.Crit Rev Microbiol. 2003;29(4):333-49. doi: 10.1080/713608018. Crit Rev Microbiol. 2003. PMID: 14636043 Review.
Cited by
-
Functional antibodies elicited by two heptavalent pneumococcal conjugate vaccines in the Finnish Otitis Media Vaccine Trial.Infect Immun. 2007 Apr;75(4):1794-800. doi: 10.1128/IAI.01673-06. Epub 2007 Jan 29. Infect Immun. 2007. PMID: 17261612 Free PMC article. Clinical Trial.
-
Kinetics and avidity of antibodies evoked by heptavalent pneumococcal conjugate vaccines PncCRM and PncOMPC in the Finnish Otitis Media Vaccine Trial.Infect Immun. 2005 Jan;73(1):369-77. doi: 10.1128/IAI.73.1.369-377.2005. Infect Immun. 2005. PMID: 15618174 Free PMC article. Clinical Trial.
-
Salivary antibodies induced by the seven-valent PncOMPC conjugate vaccine in the Finnish Otitis Media Vaccine Trial.BMC Infect Dis. 2005 May 27;5:41. doi: 10.1186/1471-2334-5-41. BMC Infect Dis. 2005. PMID: 15921511 Free PMC article. Clinical Trial.
-
Protein carriers of conjugate vaccines: characteristics, development, and clinical trials.Hum Vaccin Immunother. 2013 Dec;9(12):2505-23. doi: 10.4161/hv.26109. Epub 2013 Aug 16. Hum Vaccin Immunother. 2013. PMID: 23955057 Free PMC article. Review.
-
Subclass distribution of natural salivary IgA antibodies against pneumococcal capsular polysaccharide of type 14 and pneumococcal surface adhesin A (PsaA) in children.Clin Exp Immunol. 2006 Mar;143(3):543-9. doi: 10.1111/j.1365-2249.2006.03009.x. Clin Exp Immunol. 2006. PMID: 16487254 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous